Sugi Predict

Sugi Predict / Compounds / SCHEMBL358711

SCHEMBL358711

SCHEMBL358711

COC(=O)c1cccc(C=O)c1[N+](=O)[O-]

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.47
▸ SMN1; SMN2 Q16637 4/20 0.47
▸ MEN1 O00255 2/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ ERN1 O75460 3/20 0.46
▸ POLB P06746 2/20 0.44
▸ RAB9A P51151 2/20 0.44
▸ PIM1 P11309 1/20 0.43
▸ PIM3 Q86V86 1/20 0.43
▸ HPGD P15428 1/20 0.43
▸ MAPT P10636 1/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42
▸ LMNA P02545 2/20 0.41
▸ TSHR P16473 1/20 0.41
▸ BRAF P15056 1/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ CFTR P13569 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16959260 0.89 SMN1; SMN2 (0.48) ALDH1A1SMN1; SMN2MEN1KMT2APOLB
SCHEMBL9754355 0.89 ALDH1A1 (0.40) ALDH1A1SMN1; SMN2MEN1KMT2AERN1
SCHEMBL16635495 0.88 BRAF (0.47) ALDH1A1SMN1; SMN2MEN1KMT2AERN1
SCHEMBL16962614 0.87 SMN1; SMN2 (0.46) ALDH1A1SMN1; SMN2MEN1KMT2APOLB
SCHEMBL9099491 0.86 ERN1 (0.47) ALDH1A1SMN1; SMN2MEN1KMT2AERN1
SCHEMBL9524223 0.86 TSHR (0.39) ALDH1A1SMN1; SMN2MEN1KMT2AERN1
SCHEMBL8421994 0.85 ALDH1A1 (0.55) ALDH1A1SMN1; SMN2MEN1KMT2APOLB
SCHEMBL29220999 0.84 MAPT (0.50) ALDH1A1SMN1; SMN2MEN1KMT2AERN1
SCHEMBL25517668 0.84 SMN1; SMN2 (0.44) ALDH1A1SMN1; SMN2MEN1KMT2APOLB
SCHEMBL2142577 0.82 ERN1 (0.50) ALDH1A1MEN1KMT2AERN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110407704-B Synthetic method of 3-formyl-2-nitrobenzoic acid methyl ester 常州沃腾化工科技有限公司 2022-05-17 — — CN claimed
WO-2025017711-A1 AN IMPROVED PROCESS FOR THE PREPARATION OF NIRAPARIB TOSYLATE MONOHYDRATE NATCO PHARMA LIMITED (IN) 2025-01-23 — — WO disclosed
CN-118271233-A Nilaparil manufacturing method 特沙诺有限公司 2024-07-02 — — CN disclosed
EP-3668857-B1 PROCESSES FOR THE PREPARATION OF NIRAPARIB AND INTERMEDIATES THEREOF TEVA PHARMACEUTICALS INT GMBH (CH) 2023-07-05 — — EP disclosed
US-11629137-B2 Methods of manufacturing of niraparib TESARO, INC. (US) 2023-04-18 — — US disclosed
CN-115611901-A An azepine compound or a pharmaceutically acceptable salt thereof, and preparation method and application thereof 华南理工大学 2023-01-17 — — CN disclosed
CN-113637002-B Preparation method of Nilaparib 天津太平洋化学制药有限公司 2022-09-30 — — CN disclosed
CN-106008460-B Pharmaceutically acceptable salts of 2- {4- [ (3S) -piperidin-3-yl ] phenyl } -2H-indazole-7-carboxamide 默沙东公司 2022-08-12 — — CN disclosed
EP-3615513-B1 METHODS OF MANUFACTURING OF NIRAPARIB TESARO INC (US) 2022-07-20 — — EP disclosed
CN-110407704-B Synthetic method of 3-formyl-2-nitrobenzoic acid methyl ester 常州沃腾化工科技有限公司 2022-05-17 — — CN disclosed
WO-2008084261-A1 AMIDE SUBSTITUTED INDAZOLES AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2008-07-17 — — WO disclosed
US-20080167345-A1 Anticancer, antiinflammatory, antitumor agents, diabetes, neurodegenerative diseases, retroviral infection, retinal damage or skin senescence and UV-induced skin damage; protecting against the toxicity of chemotherapy; 2-(4-Piperidin-3-ylphenyl)2H-indazole-7-carboxamide MERCK SHARP & DOHME LLC 2008-07-10 — — US disclosed
WO-2007113596-A1 AMIDE SUBSTITUTED INDAZOLE AND BENZOTRIAZOLE DERIVATIVES AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2007-10-11 — — WO disclosed
US-20070106081-A1 Bicyclic derivatives as ppar modulators ELI LILLY AND COMPANY 2007-05-10 — — US disclosed
US-20070106081-A1 Bicyclic derivatives as ppar modulators ELI LILLY AND COMPANY 2007-05-10 — — US disclosed
US-20070106081-A1 Bicyclic derivatives as ppar modulators ELI LILLY AND COMPANY 2007-05-10 — — US disclosed
EP-1706386-A1 BICYCLIC DERIVATIVES AS PPAR MODULATORS ELI LILLY AND COMPANY (US) 2006-10-04 — — EP disclosed
WO-2005066136-A1 BICYCLIC DERIVATIVES AS PPAR MODULATORS ELI LILLY AND COMPANY (US) 2005-07-21 — — WO disclosed
EP-0523067-A1 CROP-SELECTIVE HERBICIDAL SULFONAMIDES E.I. DU PONT DE NEMOURS AND COMPANY (US) 1993-01-20 — — EP disclosed
WO-1991015478-A1 CROP-SELECTIVE HERBICIDAL SULFONAMIDES E.I. DU PONT DE NEMOURS AND COMPANY (US) 1991-10-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167345-A1 Anticancer, antiinflammatory, antitumor agents, diabetes, neurodegenerative diseases, retroviral infection, retinal damage or skin senescence and UV-induced skin damage; protecting against the toxicity of chemotherapy; 2-(4-Piperidin-3-ylphenyl)2H-indazole-7-carboxamide PARP1, PARP2, PARP11 ALDH1A1 203/4885SMN1; SMN2 620/4885MEN1 4164/4885
US-20070106081-A1 Bicyclic derivatives as ppar modulators PPARD, PPARA, PPARG ALDH1A1 849/4885SMN1; SMN2 4793/4885MEN1 4882/4885
US-11629137-B2 Methods of manufacturing of niraparib PARP2, PARP1, PARP3 ALDH1A1 622/4885SMN1; SMN2 2184/4885MEN1 2505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.